Histamine Dihydrochloride

CHEMBL1533310 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

184.1 g/mol

LogP

—

Phase

4

This is the dihydrochloride salt form of histamine, used in an approved combination therapy with interleukin-2 for the treatment of acute myeloid leukemia in remission. It works by protecting natural killer cells and T-cells from reactive oxygen species produced by monocytes, thereby enhancing the anti-cancer immune response. The salt form is used for pharmaceutical stability.

Moleküler Ağırlık

184,0600 g/mol

TPSA

54,70 Å²

Terapötik Alanlar

Melanoma Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Glaucoma Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Asthma Chronic Obstructive Pulmonary Disease Alzheimer's Disease Migraine Schizophrenia Bipolar Disorder Gastroesophageal Reflux Disease Psoriasis Multiple Sclerosis Obesity Lymphoma Type 2 Diabetes Hypertension Breast Cancer Atopic Dermatitis Chronic Pain Heart Failure Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

Cl.Cl.NCCc1c[nH]cn1

InChI

InChI=1S/C5H9N3.2ClH/c6-2-1-5-3-7-4-8-5;;/h3-4H,1-2,6H2,(H,7,8);2*1H

Molecular Formula

C5H11Cl2N3

HBD / HBA

4 / 2

Döndürülebilir Bağlar

2

Ağır Atomlar

10

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

This is the dihydrochloride salt form of histamine, used in an approved combination therapy with interleukin-2 for the treatment of acute myeloid leukemia in remission. It works by protecting natural killer cells and T-cells from reactive oxygen species produced by monocytes, thereby enhancing the anti-cancer immune response. The salt form is used for pharmaceutical stability.

Yes, Histamine Dihydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1533310. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5818. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Histamine Dihydrochloride PillFYI'da

Yapı

Hızlı Veriler

Formül: C5H11Cl2N3
Eş Anlamlılar: 45

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.